Leukeran

Chlorambucil, the active ingredient in Leukeran, is an alkylating agent (nitrogen mustard) presented as an oral formulation for oral use. It is employed in the treatment of certain hematologic malignancies, including chronic lymphocytic leukemia and various lymphomas, in adult patients.

GNH USA supplies Leukeran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with established quality‑assured distribution channels and regulatory compliance across EU and other markets. The company ensures product integrity through rigorous testing and secure logistics.

Leukeran (chlorambucil) is used in the management of hematologic cancers, primarily targeting malignant lymphoid and myeloid cells. - Chronic lymphocytic leukemia (CLL): reduces disease progression and prolongs survival in adult patients. - Hodgkin's lymphoma: contributes to remission when used as part of combination chemotherapy regimens. - Non‑Hodgkin's lymphoma: provides disease control in selected indolent subtypes. - Chronic myelogenous leukemia (CML) (off‑label): may be employed in patients intolerant to standard tyrosine‑kinase inhibitors.

Chlorambucil may cause a range of adverse reactions, varying from mild to potentially life‑threatening. Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Myelosuppression: decreased white blood cells, anemia, or thrombocytopenia. - Fatigue: generalized tiredness affecting daily activities. - Alopecia: temporary hair loss. - Mucositis: inflammation of the mouth lining. Serious or Rare Side Effects: - Secondary malignancies: increased risk of therapy‑related cancers. - Severe infections: due to profound neutropenia. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Hepatotoxicity: elevated liver enzymes or hepatic dysfunction.

When prescribing chlorambucil, clinicians should observe several safety precautions to minimize risks. - Baseline blood counts: obtain complete blood count before initiating therapy. - Renal function: assess creatinine clearance and adjust if impairment is present. - Hepatic function: monitor liver enzymes periodically during treatment. - Pregnancy: avoid use in pregnant women; discuss contraception with women of childbearing potential. - Drug interactions: review concomitant medications for potential additive myelosuppression. - Store at ambient temperature: keep tablets in original container, protect from moisture and light.

Chlorambucil can interact with other medicines, influencing its efficacy or toxicity. Major Interactions (Avoid): - Antimetabolites (e.g., methotrexate): combined use markedly increases myelosuppression. - Live vaccines: heightened risk of infection due to immunosuppression. Moderate Interactions (Monitor Closely): - CYP2C9 inhibitors (e.g., fluconazole): may raise chlorambucil plasma levels. - Anticoagulants (e.g., warfarin): enhanced bleeding risk from platelet suppression. - Allopurinol: can potentiate bone marrow toxicity.